Quelltext der Seite Alimta price3680610

Doctors and patients may finally be turning a corner in the war against cancer, says a new report released by the American Cancer Society (ACS).

The report, released early this year, shows that colorectal cancer deaths declined for the second year in a row.

Colorectal cancer is the third most common cancer diagnosed in American men and women and, at one time, went largely undetected until it was too late to hope for survival. Suzanne Lawrence is one patient who lived to tell others how she fought cancer.

After a colonoscopy, Lawrence, an active 45-year-old, was diagnosed with colon cancer. Soon after, the married, working mother of three underwent surgery to remove the tumor.

At a follow-up exam, her oncologist, Dr. John Marshall, chief of Hematology and Oncology at Lombardi Comprehensive Cancer Center, Georgetown University, checked for additional cancerous cells and found something disturbing-one of the lymph nodes was cancerous, showing that the disease had spread beyond her colon.

Although she was diagnosed with stage III colorectal cancer, Lawrence remained optimistic about her prognosis.

Dr. Marshall recommended Lawrence enroll in a clinical trial studying Avastin combined with intravenous 5FU-based chemotherapy for stage III colorectal cancer. Lawrence decided to participate in the trial and was randomized to receive Avastin plus the chemotherapy, which is approved by the U. S. Food and Drug Administration (FDA) for the first or second line treatment of patients with metastatic colorectal cancer. [http://www.avastina.com alimta]